Sarepta Therapeutics Inc Issues FY 2013 Guidance Below Analysts' Estimates

Sarepta Therapeutics Inc announced that for fiscal 2013, it expects revenue to be in the range of $18 to $24 million and that loss from operations to be in the $85 to $115 million range. The revenue guidance is based on the assumption that Sarepta will continue to receive funding from its current government contracts for Marburg. If Sarepta does not continue to receive this funding, its revenue guidance would change significantly. Additionally, the operating loss guidance is largely based on continuing development and scale up manufacturing for eteplirsen and our follow-on DMD drugs. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $31 million and net income of $(45) million for fiscal 2013.